|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest miR-122 play important roles in goose fatty liver by targeting some of the genes related to lipid metabolism.
|
29182758 |
2018 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice given injections of the anti-MIR122 before ethanol feeding had increased steatosis, inflammation, and serum levels of alanine aminotransferase compared with mice given a control vector.
|
28987423 |
2018 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Are miRNA-103, miRNA-107 and miRNA-122 Involved in the Prevention of Liver Steatosis Induced by Resveratrol?
|
28375178 |
2017 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum miR-122 levels (calibrated relative to the median levels of patients) partly affected severity of steatosis, ballooning, lobular inflammation, and stage.
|
27074850 |
2016 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regarding circulating levels, MO patients with NASH showed higher miR122 levels than MO with simple steatosis (SS).
|
27669236 |
2016 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results suggested that ACF may inhibit hepatic steatosis via miR‑122‑induced downregulation of FASN in vivo and in vitro.
|
27081834 |
2016 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum miR-122, -192 and -34a levels were correlated with steatosis (R = 0.302, 0.323 and 0.470, respectively, <i>P</i> < 0.05) and inflammatory activity (R = 0.445, 0.447 and 0.517, respectively, <i>P</i> < 0.01); only serum miR-16 levels were associated with fibrosis (R = 0.350, <i>P</i> < 0.05) in patients with NAFLD.
|
27956809 |
2016 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Liver miR-122 expression was 10-fold (p<0.03) downregulated in NASH compared with SS and was preferentially expressed at the edge of lipid-laden hepatocytes.
|
24973316 |
2015 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The same expression pattern was observed in different stages and grades of liver disease. miR-122 was up-regulated in women relative to men and associated to portal inflammation, miR-122 and miR-126 correlated with serum HCV load and miR-136 and miR-122 correlated with the presence of steatosis. miR-126 and miR-136 were differentially expressed between different modes of HCV transmission.
|
25065618 |
2015 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-122 was also decreased in clinical samples of liver tissue showing macrovesicular steatosis and HCC, being consistent with the findings in the NASH model mice.
|
25117675 |
2014 |
|
Steatohepatitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutant mice with knockout (KO) of the miR-122 locus developed steatohepatitis due to increased triglyceride (TG) synthesis and decreased TG secretion from hepatocytes, and eventually developed HCC.
|
24531873 |
2014 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serum level of miR-122 was correlated with the severity of liver steatosis.
|
23727030 |
2013 |
|
Steatohepatitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that mice lacking the gene encoding miR-122a (Mir122a) are viable but develop temporally controlled steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC).
|
22820290 |
2012 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis.
|
23236228 |
2012 |
|
Steatohepatitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Again, miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis.
|
21886843 |
2011 |